Ubs Oconnor LLC Xenon Pharmaceuticals Inc. Transaction History

Ubs Oconnor LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $285,352 - $334,717	-6,689 Reduced 45.58%	7,987 $343,000
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $975,800 - $1.58 Million	-34,000 Reduced 69.85%	14,676 $675,000
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $341,599 - $397,299	10,000 Added 25.86%	48,676 $1.66 Million
Q2 2023 Aug 14, 2023	BUY	$34.84 - $43.54 $1.35 Million - $1.68 Million	38,676 New	38,676 $1.49 Billion
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $32,824 - $39,583	-981 Reduced 1.52%	63,391 $2.27 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $336,021 - $400,766	10,164 Added 18.75%	64,372 $0
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $1.29 Million - $1.67 Million	-42,000 Reduced 43.66%	54,208 $1.96 Billion
Q2 2022 Aug 12, 2022	BUY	$25.44 - $35.16 $1.37 Million - $1.89 Million	53,706 Added 126.36%	96,208 $2.93 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $1.07 Million - $1.41 Million	42,502 New	42,502 $1.3 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.